Company news

Trevi Therapeutics, Inc. news in 2024

Trevi Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

December 15, 2024

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

December 11, 2024

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

December 2, 2024

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

November 20, 2024

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

November 5, 2024

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

October 29, 2024

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

October 20, 2024

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

October 14, 2024

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program

October 2, 2024

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer

September 29, 2024

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024

September 25, 2024

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024

September 3, 2024

Trevi Therapeutics to Participate in September Investor and Medical Conferences

August 27, 2024

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance

August 7, 2024

Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024

July 31, 2024

Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events

July 1, 2024

Trevi Therapeutics to Participate in Upcoming Conferences

May 8, 2024

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024

Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024

April 30, 2024

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference

April 8, 2024

Trevi Therapeutics to Participate in Upcoming April Events

April 3, 2024

Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

April 1, 2024

Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates

March 19, 2024

Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024

March 12, 2024

Trevi Therapeutics to Participate in Upcoming March Events

February 27, 2024

Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 5, 2024

Trevi Therapeutics Provides Business Updates

January 3, 2024

Calls in 2024

Decks in 2024